date:Sep 27, 2013
arket dynamics and include a new group EBITDA margin target of 14-15% with a ROCE target of 11-12%.
Furthermore, DSM will outline its priorities for the coming two years:
Completing the strategic actions for DSM Pharmaceutical Products and Polymer Intermediates
Integrating the acquired companies, capturing full synergies and driving organic growth
Improving the operational performance of its businesses
During the Capital Markets Day DSM will also further detail the current market condition